1957) in tumour tissues calls for special attention. It appears that since adenine is a constituent of nucleic acids and also of pyridine nucleotides, any drain on this precursor from the metabolic pool in the nucleic acid synthesis of tumour may deprive the host tissues of its availability for pyridine nucleotide synthesis.
Our own findings on levels of activity of the choline-dehydrogenase in the livers of tumour-bearing animals were considerably lower than those observed in the tissues of normal animals. It was further shown that this inherently diminished enzyme activity could be reversed by fortification of the medium with DPN. In the present communication two problems have been investigated: (i) the influence of the tumour on the host tissues with respect to the pyridine nucleotide levels and (ii) the availability or non-availability of adenine nucleotides in the synthesis of pyridine nucleotides in host tissues. For this purpose, two types of transplantable tumours: (a) fast growing ascites Yoshida sarcoma and (b) comparatively slow growing fibrosarcoma have been used in Wistar rats and Swiss mice respectively.
MATERIAL AND METHODS
Transplantable fibrosarcoma was maintained by subcutaneous injections of tumour homogenates in 6-8-week-old Swiss mice. The tumour attains an appreciable size in about 21 days. Yoshida sarcoma (ascites) obtained through the courtesy of Professor H. Druckrey, of Freiburg, Germany, was maintained by intraperitoneal transfer in Wistar rats. This tumour grows rapidly and results in the death of animals in 7-8 days.
The levels of pyridine nucleotides in the livers and spleens of normal and tumour-bearing animals have been estimated according to the method of Huff and Perlzweig (1947) as modified by Dianzani (1955) . In another experiment with Yoshida sarcoma the pyridine nucleotide levels of host tissues have been investigated at different intervals of time after transplantation. The optimum time and dose of nicotinamide required was determined in auxiliary experiments by injecting intraperitoneally 250, 500, and 1000 mg. of nicotinamide per kg. of body weight and estimating the pyridine nucleotide synthesis in the livers and spleens 3, 6, 12 and 18 hours afterwards. In case of Swiss mice, nicotinamide was administered at the dose of 500 mg. per kg. of body weight as suggested by Kaplan et al. (1956) .
RESULTS AND DISCUSSION
The levels of pyridine nucleotides in the livers and spleens of control and tumour-bearing animals are presented in Table I . It will be seen from this that the presence of the tumour brings about a lowering of pyridine nucleotide levels in the host tissues. In case of slow growing fibrosarcoma in Swiss mice the lowering in the levels of pyridine nucleotides is to the extent of 16.4 and 26-1 per cent in the livers and spleens respectively. In the fast growing Yoshida sarcoma, however, the effects are more pronounced, the lowering in livers and spleens being to the extent of 43-1 and 18-0 per cent respectively. It will be seen from Table II The influence exerted by Yoshida sarcoma on the synthesis of pyridine nucleotides in the host spleen is given in Fig. 1 . It will be seen that there is a 0. decreased utilization of nicotinamide for pyridine nucleotide synthesis in the host tissues. During the 3 hour period, the normal spleens synthesize 548 pg. of pyridine nucleotide per g. of tissue, whereas the spleens from the tumour-bearing animals show a negligible response. The differences in the utilization of nicotinamide in these two groups become more marked after 12 hours which is the optimum period for pyridine nucleotide synthesis (Table IV) . Thus, while the These results clearly demonstrate that the presence of fibrosarcoma and Yoshida sarcoma in the body impairs the utilization of nicotinamide for pyridine nucleotide synthesis in host tissues. Whether this is due to a release of an inhibitory substance by the tumour as has recently been suggested by Waravdekar and Powers (1957) , or whether it originates from a competition between the nucleic acids and the pyridine nucleotides for adenine moiety of the metabolic pool is yet undecided and further work is in progress to elucidate this. 
